Mastitis Market- Global Industry Analysis and Forecast (2025-2032)

Mastitis Market size was valued at USD 1.60 Bn. in 2024 and the Mastitis revenue is expected to grow at a CAGR of 5.8% from 2025 to 2032, reaching nearly USD 2.52 Bn. by 2032.

Format : PDF | Report ID : SMR_2101

Mastitis Market Overview:

Mastitis is a condition where there is inflammation in breast tissue, which can sometimes be accompanied by an infection. While mastitis mostly affects women who are breastfeeding, it can also occur in women who are not breastfeeding and even in men. Breast inflammation can present as pain, swelling, warmth, and redness or fever and chills may occur in a patient. It is more prevalent at one to three days following childbirth but can also affect women who have not recently given birth as well as those who have reached menopause. Mastitis is majorly caused by blocked milk ducts, Bacteria infections (among others) in the breasts.

Based on the data provided to us by Nestle Nutrition Institution, we estimate that up to 30% of all breastfeeding women develop Lactation Mastitis, the rates varying across populations; it may be as low as 2% or as high as 10%. Around 0.1–3% of them end up having puss mastitis.

The Mastitis Market report provides a detailed analysis of the strong competition, challenges and dominant sectors in the market. The key findings of the report include market size and forecasts period with current environmental and other developments that affect the Market. The Mastitis Market is segmented into type, Treatment and end-user which is presented with the help of graphs and figures for a better understanding of the fastest-growing segments. The report used both quantitative and qualitative methods for the analysis of the industry. The market size and estimations along with the growth rate are covered in the report. The bottom-up approach was used for market estimations which were validated by various segments.

Mastitis Market snapshot

To get more Insights: Request Free Sample Report

Mastitis Market Dynamics:

Driving Forces behind the Booming Mastitis Market: Prevalence, Diagnostics, and Innovative Therapies

The major factors responsible for the market growth of bovine mastitis are: increased diseases incidence rate, a broad range of animal health products introduced into the market and technological advancements in drugs discovery and development. Significant growth is being witnessed by the mastitis market due to increasing prevalence, especially in lactating women, fuelling the demand for effective treatment options. Factors such as improper breastfeeding techniques and poor hygiene contribute to the rising cases of mastitis. People have started to notice mastitis disease due to the problems it may bring like breast abscesses or sepsis, this factor prompting early diagnosis to be prioritized more.

Growth in the market for this condition is also attributed to more sophisticated diagnostic methods based on ultrasound and blood analyses which enhance precision during diagnosis. Resistance has been spreading through bacterial populations to conventional antibiotics used in mastitis therapy, a factor contributing to both emergence of new therapies, development of better management protocols for mastitis control as well as environmental conservation measures that would mitigate antibiotic resistance risks.

Mastitis Market Challenges

Key Challenges Facing the Mastitis Market: Raw Material Volatility, Competition from Alternatives, High Capital Investments, and Environmental Concerns

Several important problems make it hard for the mastitis market to grow. One of the biggest barriers is the growth of antibiotic resistance, where over time, the bacteria that cause mastitis have started to show resistance against common antibiotics available hence limited options for treatment. Poor awareness and lack of proper screening, particularly in developing areas lead to late diagnosis hence treating thus worsening the situation may develop complications. Besides, patients from underprivileged areas have an issue of high costs for treatment with advanced therapies and procedures as a diagnosis, which makes it difficult for them to get the best treatment.

The strict regulation criteria for new mastitis treatments approval also represent an obstacle as they delay the marketing of innovative therapies which in turn slows down the provision of modernized treatments. In distant locations, the largest problem of unskilled medics and inadequate healthcare centers is that they contribute to be late in diagnosing and dealing with mastitis in time. This only makes the problem of the market more complex.

Mastitis Market Segment Analysis:

By Type, Based on the type, the mastitis market can be segmented by type into bovine mastitis and human mastitis. Bovine mastitis, affecting dairy cattle, accounts for a significant share of the market, driven by the high prevalence of the condition in dairy herds and the substantial economic losses it causes for the dairy industry. Human mastitis, primarily affecting lactating women, is also a crucial segment, with increasing awareness and demand for effective treatment options contributing to its growth.

Mastitis Market Regional Insight:

The mastitis market exhibits regional variations influenced by healthcare infrastructure, livestock management practices, and regulatory frameworks. In North America and Europe, stringent regulatory standards and advanced veterinary healthcare systems drive market growth, supported by high awareness among dairy farmers. Asia-Pacific, led by countries like India and China, experiences significant market expansion due to rising dairy production and increasing adoption of veterinary services. Latin America and the Middle East & Africa regions are emerging markets with growing investments in livestock health and dairy farming.

Mastitis Market Competitive Landscape:

In June 2022: A new Biological Development Centre (BDC) at Boehringer Ingelheim's research development locations in Biberach, Germany, was revealed with a 230-million-euro investment. The BDC will be the company's first BDC.
In June 2021: Tavocept, an experimental novel medication developed by BioNumerik Pharmaceuticals, was approved by the Food and Drug Administration for use in both cancer and non-oncology purposes.

Mastitis Market Scope:

Mastitis Market
Market Size in 2024	USD 1.60 Bn.
Market Size in 2032	USD 2.52 Bn.
CAGR (2025-2032)	5.8 %
Historic Data	2019-2024
Base Year	2024
Forecast Period	2025-2032
Segments	By Type Bovine Contagious Mastitis Environmental Mastitis Opportunist Mastitis Human Non-Infectious Mastitis Infectious Mastitis
	By Treatment Bovine Antibiotics Vaccines Human Pain Relievers Antibiotics
	By End User Veterinary Centers Hospital & Clinics
Regional Scope	North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America

Mastitis Market Key Players:

Bayer AG
Zoetis Inc.
Boehringer Ingelheim GmbH
Merck Co. & Inc.
Astellas Pharma Inc.
Pfizer Inc.
Novartis AG
IDEXX Laboratories
MSD Animal Health,
DeLaval International AB
CEVA Santé Animale
Vetoquinol
HIPRA
Kyoritsu Seiyaku Corporation
Ceva Sante Animale
Thermo Fisher Scientific
Laboratorios SYVA
IDEXX Laboratories
Elanco Animal Health
Hester Biosciences Limited

Buy Now

Request For Free sample

Frequently Asked Questions

1. What are the growth drivers for the Mastitis Market?

Driving Forces behind the Booming Mastitis Market: Prevalence, Diagnostics, and Innovative Therapies.

2. What are the challenge of the Mastitis Market?

Raw Material Volatility, Competition from Alternatives, High Capital Investments, and Environmental Concerns are the challenge in the Mastitis Market.

3. What is the projected Mastitis Market size & and growth rate of the Market?

The Market size was valued at USD 1.60 Billion in 2024 and the total Market revenue is expected to grow at a CAGR of 5.8 % from 2025 to 2032, reaching nearly USD 2.52 Billion.

4. What segments are covered in the Market report?

The segments covered in the market report are by Type, By Treatment and By Nature.

1.   Research Methodology
1.1   Research Data
1.1.1.   Primary Data
1.1.2.   Secondary Data
1.2.   Market Size Estimation
1.2.1.   Bottom-Up Approach
1.2.2.   Top-Down Approach
1.3.   Market Breakdown and Data Triangulation
1.4.   Research Assumption

2.   Mastitis Market Executive Summary
2.1.   Market Overview
2.2.   Market Size (2024) and Forecast (2025 – 2032) and Y-O-Y%
2.3.   Market Size (USD) and Market Share (%) – By Segments and Regions

3.   Global Mastitis Market: Competitive Landscape
3.1.   SMR Competition Matrix
3.2.   Key Players Benchmarking
3.2.1.   Company Name
3.2.2.   Headquarter
3.2.3.   Business Segment
3.2.4.   End-user Segment
3.2.5.   Y-O-Y%
3.2.6.   Revenue (2024)
3.2.7.   Profit Margin
3.2.8.   Market Share
3.2.9.   Company Locations
3.3.   Market Structure
3.3.1.   Market Leaders
3.3.2.   Market Followers
3.3.3.   Emerging Players
3.4.   Consolidation of the Market
3.4.1.   Strategic Initiatives and Developments
3.4.2.   Mergers and Acquisitions
3.4.3.   Collaborations and Partnerships

4.   Mastitis Market: Dynamics
4.1.   Mastitis Market Trends by Region
4.1.1.   North America
4.1.2.   Europe
4.1.3.   Asia Pacific
4.1.4.   Middle East and Africa
4.1.5.   South America
4.2.   Mastitis Market Drivers
4.3.   Mastitis Market Restraints
4.4.   Mastitis Market Opportunities
4.5.   Mastitis Market Challenges
4.6.   PORTER’s Five Forces Analysis
4.6.1.   Intensity of the Rivalry
4.6.2.   Threat of New Entrants
4.6.3.   Bargaining Power of Suppliers
4.6.4.   Bargaining Power of Buyers
4.6.5.   Threat of Substitutes
4.7.   PESTLE Analysis
4.7.1.   Political Factors
4.7.2.   Economic Factors
4.7.3.   Social Factors
4.7.4.   Technological Factor
4.7.5.   Legal Factors
4.7.6.   Environmental Factors
4.8.   Technological Roadmap
4.9.   Regulatory Landscape
4.9.1.   Market Regulation by Region
4.9.1.1.   North America
4.9.1.2.   Europe
4.9.1.3.   Asia Pacific
4.9.1.4.   Middle East and Africa
4.9.1.5.   South America
4.9.2.   Impact of Regulations on Market Dynamics

5.   Mastitis Market: Global Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
5.1.   Mastitis Market Size and Forecast, by Type (2024-2032)
5.1.1.   Bovine
5.1.1.1.   Contagious Mastitis
5.1.1.2.   Environmental Mastitis
5.1.1.3.   Opportunist Mastitis
5.1.2.   Human
5.1.2.1.   Non-Infectious Mastitis
5.1.2.2.   Infectious Mastitis
5.2.   Mastitis Market Size and Forecast, by Treatment (2024-2032)
5.2.1.   Bovine
6.1.1.1.   Antibiotics
6.1.1.2.   Vaccines
6.1.2.   Human
6.2.1.1.   Pain Relievers
6.2.1.2.   Antibiotics
5.3.   Mastitis Market Size and Forecast, by End User (2024-2032)
5.3.1.   Veterinary Centers
5.3.2.   Hospital & Clinics
5.4.   Mastitis Market Size and Forecast, by Region (2024-2032)
5.4.1.   North America
5.4.2.   Europe
5.4.3.   Asia Pacific
5.4.4.   Middle East and Africa
5.4.5.   South America

6.   North America Mastitis Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
6.1.   North America Mastitis Market Size and Forecast, by Type (2024-2032)
6.1.1.   Bovine
6.1.1.1.   Contagious Mastitis
6.1.1.2.   Environmental Mastitis
6.1.1.3.   Opportunist Mastitis
6.1.2.   Human
6.1.2.1.   Non-Infectious Mastitis
6.1.2.2.   Infectious Mastitis
6.2.   North America Mastitis Market Size and Forecast, by Treatment (2024-2032)
6.2.1.   Bovine
6.1.2.1.   Antibiotics
6.1.2.2.   Vaccines
6.1.3.   Human
6.2.1.3.   Pain Relievers
6.2.1.4.   Antibiotics
6.3.   North America Mastitis Market Size and Forecast, by End User (2024-2032)
6.3.1.   Veterinary Centers
6.3.2.   Hospital & Clinics
6.4.   North America Mastitis Market Size and Forecast, by Country (2024-2032)
6.4.1.   United States
6.4.2.   Canada
6.4.3.   Mexico

7.   Europe Mastitis Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
7.2.   Europe Mastitis Market Size and Forecast, by Type (2024-2032)
7.3.   Europe Mastitis Market Size and Forecast, by Treatment (2024-2032)
7.4.   Europe Mastitis Market Size and Forecast, by End User (2024-2032)
7.5.   Europe Mastitis Market Size and Forecast, by Country (2024-2032)
7.5.1.   United Kingdom
7.5.2.   France
7.5.3.   Germany
7.5.4.   Italy
7.5.5.   Spain
7.5.6.   Sweden
7.5.7.   Russia
7.5.8.   Rest of Europe

8.   Asia Pacific Mastitis Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
8.2.   Asia Pacific Mastitis Market Size and Forecast, by Type (2024-2032)
8.3.   Asia Pacific Mastitis Market Size and Forecast, by Treatment (2024-2032)
8.4.   Asia Pacific Mastitis Market Size and Forecast, by End User (2024-2032)
8.5.   Asia Pacific Mastitis Market Size and Forecast, by Country (2024-2032)
8.5.1.   China
8.5.2.   S Korea
8.5.3.   Japan
8.5.4.   India
8.5.5.   Australia
8.5.6.   ASEAN
8.5.7.   Rest of Asia Pacific

9.   Middle East and Africa Mastitis Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
9.2.   Middle East and Africa Mastitis Market Size and Forecast, by Type (2024-2032)
9.3.   Middle East and Africa Mastitis Market Size and Forecast, by Treatment (2024-2032)
9.4.   Middle East and Africa Mastitis Market Size and Forecast, by End User (2024-2032)
9.5.   Middle East and Africa Mastitis Market Size and Forecast, by Country (2024-2032)
9.5.1.   South Africa
9.5.2.   GCC
9.5.3.   Egypt
9.5.4.   Rest of ME&A

10.   South America Mastitis Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
10.2.   South America Mastitis Market Size and Forecast, by Type (2024-2032)
10.3.   South America Mastitis Market Size and Forecast, by Treatment (2024-2032)
10.4.   South America Mastitis Market Size and Forecast, by End User (2024-2032)
10.5.   South America Mastitis Market Size and Forecast, by Country (2024-2032)
10.5.1.   Brazil
10.5.2.   Argentina
10.5.3.   Rest Of South America

11.   Company Profile: Key Players
11.2.   Bayer AG
11.2.1.   Company Overview
11.2.2.   Business Portfolio
11.2.3.   Financial Overview
11.2.3.1.   Total Revenue
11.2.3.2.   Segment Revenue
11.2.3.3.   Regional Revenue
11.2.4.   SWOT Analysis
11.2.5.   Strategic Analysis
11.2.6.   Recent Developments
11.3.   Zoetis Inc.
11.4.   Boehringer Ingelheim GmbH
11.5.   Merck Co. & Inc.
11.6.   Astellas Pharma Inc.
11.7.   Pfizer Inc.
11.8.   Novartis AG
11.9.   IDEXX Laboratories
11.10.   MSD Animal Health,
11.11.   DeLaval International AB
11.12.   CEVA Santé Animale
11.13.   Vetoquinol
11.14.   HIPRA
11.15.   Kyoritsu Seiyaku Corporation
11.16.   Ceva Sante Animale
11.17.   Thermo Fisher Scientific
11.18.   Laboratorios SYVA
11.19.   IDEXX Laboratories
11.20.   Elanco Animal Health
11.21.   Hester Biosciences Limited